Treatment Program Wrapper for Personalized Medicine Safety

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a need to ensure the safety and reliability of automated personalized medicine software by providing assurance that treatment decisions are appropriately isolated, based on validated data, made with respect to a consistent date/time frame, and subject to safety checks before being shared with patients.

Innovation Solution

The method involves initializing a treatment program wrapper in a software environment, which isolates the treatment program and provides runtime execution context, executes personalized therapeutic processes, routes data to a clinician portal, and outputs personalized therapeutic instructions to a user interface, ensuring safety and reliability through validation and safety checks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If automated personalized medicine software is used to improve treatment feedback frequency and make therapeutic decisions, then patient health outcomes are improved, but safety and reliability assurance becomes challenging

Engineering Contradiction:
Improvetreatment feedback frequencyVSAvoidsafety and reliability assurance
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The software system is segmented into distinct functional modules including a treatment program wrapper, isolation mechanism, data validation module, and safety check module. This segmentation allows each component to be independently verified and tested, improving reliability while maintaining high feedback frequency through automated operations.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A treatment program wrapper acts as an intermediary layer between the automated treatment decision-making process and the patient data. This wrapper provides isolation and control, ensuring that automated decisions are made safely within defined boundaries while still enabling frequent feedback loops.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If treatment decisions are made with frequent feedback based on regularly captured patient data, then personalized medicine effectiveness is improved, but the complexity of ensuring validated data and consistent date/time frame increases

Engineering Contradiction:
Improvedata validation accuracyVSAvoidsoftware system complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The system performs preliminary actions by establishing a consistent date/time frame reference before processing treatment decisions. Data validation checks are pre-configured and automatically applied to all incoming patient data, ensuring measurement precision without requiring complex real-time verification logic.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The system standardizes data parameters by enforcing a consistent date/time frame reference across all treatment decisions. This parameter standardization simplifies the validation process while maintaining high data accuracy requirements for personalized medicine effectiveness.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If isolation mechanisms are implemented to ensure treatment decisions are based on validated data, then safety is improved, but the ease of operation and implementation becomes more difficult

Engineering Contradiction:
Improvetreatment decision safetyVSAvoidimplementation ease
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The isolation mechanism extracts and separates the treatment program into a distinct, encapsulated environment with controlled data flow. This extraction ensures that only validated data enters the treatment decision process, improving safety while maintaining operational simplicity through clear boundaries and interfaces.

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentUS20250174331A1Personalised Treatment Software
Publication Date: 2025.05.29 MORCHELLA MEDICAL LTD
  • US20250174331A1 patent drawing
  • US20250174331A1 patent drawing
  • US20250174331A1 patent drawing

AI summary

A computer implemented method for providing a personalised therapeutic instruction comprising initialising a treatment program wrapper in a software environment; initialising a treatment program using the treatment program wrapper, wherein the treatment program wrapper provides runtime execution context to the treatment program and isolates the treatment program from the software environment; executing a personalised therapeutic process of the treatment program to output personalised therapeutic data; routing the personalised therapeutic data to a clinician portal using a clinician interface mechanism of the treatment program wrapper; and outputting the personalised therapeutic instruction to a user interface based on the personalised therapeutic data.